首頁 › 急性髓系白血病 › 俄克拉荷馬州 › Oklahoma City
Oklahoma City, OK 的 急性髓系白血病 臨床試驗
14 項針對 急性髓系白血病 的研究正在 Oklahoma City（約 30 英里範圍內）及其周邊地點尋找參與者。開啟研究以查看參與資格及聯絡研究團隊的方式。
官方研究文本（英文）
正在為研究招募對象嗎？將此頁面置頂展示 — $99 / 30 天 →
MYELOMATCH: A Screening Study to Assign People With Myeloid Cancer to a Treatment Study or Standard of Care Treatment Within myeloMATCH (MyeloMATCH Screening Trial)
招募中2 期
- University of Oklahoma Health Sciences Center, Oklahoma City
Collecting Blood Samples From Patients With and Without Cancer to Evaluate Tests for Early Cancer Detection
招募中觀察性研究歡迎健康志工
- Mercy Hospital Oklahoma City, Oklahoma City
Comparing Cytarabine + Daunorubicin Therapy Versus Cytarabine + Daunorubicin + Venetoclax Versus Venetoclax + Azacitidine in Younger Patients With Intermediate Risk AML (A MyeloMATCH Treatment Trial)
招募中2 期
- University of Oklahoma Health Sciences Center, Oklahoma City
Comparing New Treatments for People With Newly Diagnosed Acute Myeloid Leukemia That Has an IDH2 Gene Change (A MyeloMATCH Treatment Trial)
招募中2 期
- University of Oklahoma Health Sciences Center, Oklahoma City
Testing New Therapies for Patients With Acute Myeloid Leukemia Who Are Newly Diagnosed and Have Not Yet Started Treatment (A MyeloMATCH Treatment Trial)
招募中2 期
- University of Oklahoma Health Sciences Center, Oklahoma City
Venetoclax and HMA Treatment of Older and Unfit Adults With FLT3 Mutated Acute Myeloid Leukemia (AML) (A MyeloMATCH Treatment Trial)
招募中2 期
- University of Oklahoma Health Sciences Center, Oklahoma City
A Study to Compare Standard Chemotherapy to Therapy With CPX-351 and/or Gilteritinib for Patients With Newly Diagnosed AML With or Without FLT3 Mutations
招募中3 期
- University of Oklahoma Health Sciences Center, Oklahoma City
The Pediatric Acute Leukemia (PedAL) Screening Trial - A Study to Test Bone Marrow and Blood in Children With Leukemia That Has Come Back After Treatment or Is Difficult to Treat - A Leukemia & Lymphoma Society and Children's Oncology Group Study
招募中1/2 期
- University of Oklahoma Health Sciences Center, Oklahoma City
A Phase 1b Study of Menin Inhibitor SNDX- 5613 in Combination With Daunorubicin and Cytarabine in Newly Diagnosed Patients With Acute Myeloid Leukemia and NPM1 Mutated/FLT3 Wildtype or MLL/KMT2A Rearranged or NUP98 Alterations Disease
招募中1 期
- University of Oklahoma Health Sciences Center, Oklahoma City
Safety and Tolerability of Ziftomenib Combinations in Patients With Relapsed/Refractory Acute Myeloid Leukemia
招募中1 期
- OU Health Stephenson Cancer Center, Oklahoma City
A Multicenter Access and Distribution Protocol for Unlicensed Cryopreserved Cord Blood Units (CBUs)
招募中觀察性研究
- University of Oklahoma Health Science Center, Oklahoma City
Pilot Imaging Study of Leukemia
招募中1 期
- University of Oklahoma Health Sciences Center, Oklahoma City
A Study to Investigate the Safety and Tolerability of Ziftomenib in Combination With Venetoclax/Azacitidine, Venetoclax, 7+3, or 7+3+Quizartinib in Patients With AML
招募中1 期
- OU Health Stephenson Cancer Center, Oklahoma City
Azacitidine or Decitabine With Venetoclax for Acute Myeloid Leukemia With Prior Hypomethylating Agent Failure
招募中2 期
- University of Oklahoma Health Sciences Center, Oklahoma City
其他城市的 急性髓系白血病 試驗
- Houston, TX85 項研究
- New York City, NY51 項研究
- Boston, MA44 項研究
- Seattle, WA41 項研究
- Baldwin Park, CA40 項研究
- Columbus, OH35 項研究
- Philadelphia, PA34 項研究
- Durham, NC33 項研究
- Atlanta, GA31 項研究
- Tampa, FL29 項研究
- Chicago, IL26 項研究
- Portland, OR25 項研究
Oklahoma City 的其他研究
- 非小細胞肺癌28 項研究
- 卵巢癌28 項研究
- 子宮內膜癌25 項研究
- 大腸直腸癌22 項研究
- 前列腺癌21 項研究
- 肺癌19 項研究
- 乳癌17 項研究
- 轉移性癌症16 項研究
- 癌症（所有類型）14 項研究
- 頭頸部鱗狀細胞癌13 項研究
- 膀胱癌11 項研究
- 胰臟癌11 項研究
資料來源：ClinicalTrials.gov，擷取日期 2026年10月6日。各研究自行設定資格標準；由研究團隊決定參與者資格。